SEARCH:   Advanced

Blood, 15 March 2007, Vol. 109, No. 6, pp. 2322-2326. Prepublished online as a Blood First Edition Paper on November 7, 2006; DOI 10.1182/blood-2006-06-032284. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2006-06-032284v1 109/6/2322    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Meisel, R. Articles by Dilloo, D. Search for Related Content PubMed PubMed Citation Articles by Meisel, R. Articles by Dilloo, D. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 29, 2006 Accepted October 30, 2006 Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation Roland Meisel*, Lisa Kuypers, Uta Dirksen, Ralf Schubert, Bernd Gruhn, Gabriele Strauss, Karin Beutel, Andreas H. Groll, Ulrich Duffner, Renate Blutters-Sawatzki, Wolfgang Holter, Tobias Feuchtinger, Hans-Peter Gruttner, Horst Schroten, Stefan Zielen, Christian Ohmann, Hans-Jurgen Laws, and Dagmar Dilloo University Children's Hospital, Heinrich Heine-University, Germany University Clinic of Dusseldorf, Germany University Children's Hospital, J.W. Goethe-University, Germany University Children's Hospital, Friedrich Schiller-University, Germany Charite, Campus Virchow Klinikum, Germany University Children's Hospital, Hamburg, Germany University Children's Hospital, Germany University Children's Hospital, Justus Liebig-University, Germany University Children's Hospital, Friedrich Alexander-University Erlangen-Nurnberg, Germany * Corresponding author; email: meisel{at}med.uni-duesseldorf.de. Following allogeneic hematopoietic stem cell transplantation (alloHSCT) children are at risk for life-threatening pneumococcal infections. Whereas vaccination with polysaccharide vaccines fails to elicit protective immunity in most alloHSCT recipients, pneumococcal conjugate vaccines may effectively prevent invasive disease by eliciting T-cell-dependent antibody responses. Here we report safety and immunogenicity in fifty-three children immunized with a regimen of three consecutive doses of a heptavalent pneumococcal conjugate vaccine (7vPCV) in monthly intervals starting 6-9 months after alloHSCT. Immunization was well tolerated with no vaccine-related serious adverse events. Serologic response rates evaluable in fourty-three patients ranged from 41.9-86.0% and 58.1-93.0% after two and three vaccinations respectively, with 55.8 and 74.4% of patients achieving protective antibody levels to all seven vaccine serotypes. Our study provides first evidence, that vaccination with 7vPCV is safe and elicits protective anti-pneumococcal antibody responses in pediatric recipients of related or unrelated donor alloHSCT within the 1st year following transplantation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020